Neupro (Parkinson's Disease) - Forecast and Market Analysis to 2022
|出版日期||內容資訊||英文 62 Pages
|Neupro(帕金森氏症治療藥):市場預測與分析 Neupro (Parkinson's Disease) - Forecast and Market Analysis to 2022|
|出版日期: 2014年03月31日||內容資訊: 英文 62 Pages||
UCB所開發的Neupro，是透過穿皮貼片劑(貼片)供給rotigotine的藥劑，已核准為早期∼晚期突發性帕金森氏症的症候治療藥，也用於中至重度的不寧腿症候群(RLS)緩和藥。rotigotine是非雌激素D2·D3受體激動劑，具有對D2的選擇性(Chen et al., 2009)。此外也具有腎上腺素和血清素活性。
Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
Neupro, developed by UCB, delivers rotigotine by a transdermal patch. It is approved to treat the signs and symptoms of early- to advanced-stage idiopathic Parkinson's disease and used in moderate to severe restless legs syndrome. Rotigotine is a non-ergoline D2 and D3 receptor agonist with selectivity for D2 (Chen et al., 2009). It also has adrenergic and serotonergic activity.